Overland ADCT BioPharma Doses First Patient in Zynlonta’s Phase III LOTIS-5 Study for DLBCL
Overland ADCT BioPharma (CY) Ltd, a joint venture between China’s Overland Pharmaceuticals and Switzerland’s ADC...
Triastek Partners with Eli Lilly to Explore 3D Printing for GI Drug Delivery
China-based Triastek Inc., a pharmaceutical 3D printing specialist, announced a partnership with US firm Eli...
Zhejiang Medicine’s ARX305 ADC Receives Clinical Trial Approval for CD70-Positive Cancers
China-based Zhejiang Medicine Co., Ltd (SHA: 600216) announced that its subsidiary NovoCodex Biopharmaceuticals Ltd has...
GenScript ProBio Partners with ACT Therapeutics on CAR-T Cell Therapy Development
GenScript ProBio, a global Contract Development and Manufacturing Organization (CDMO), announced a memorandum of understanding...
Abbisko Therapeutics’ ABSK021 Receives BTD for Giant Cell Tumor Treatment
Shanghai-based Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that its Category 1 drug ABSK021 has...
NMPA Reclassifies Glucosamine Sulfate to OTC, Mandates Label Revisions
China’s National Medical Products Administration (NMPA) announced that potassium glucosamine sulfate has been reclassified from...
China’s JPO Launches VBP Round for Orthopedic Spine Consumables
China’s Joint Procurement Office (JPO) announced plans on July 11 to conduct a volume-based procurement...
HutchMed’s Orpathys-Tagrisso Combo Shows Promise in NSCLC at WCLC
China-based HutchMed (NASDAQ: HCM, HKG: 0013) announced the publication of an abstract detailing the SAVANNAH...
Junshi Biosciences’ JS203 Bispecific Antibody Receives NMPA Green Light for NHL Study
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that the National Medical Products Administration (NMPA)...
Eli Lilly’s Trulicity + Insulin Combo Meets Goals in China’s AWARD-CHN3 Study
Eli Lilly (NYSE: LLY) announced that its Phase III AWARD-CHN3 study of Trulicity (dulaglutide) combined...
China’s 7th VBP Round Yields 65.5% Drug Price Cuts, Foreign Firms Secure Bids
China’s 7th national volume-based procurement (VBP) round concluded with winning bids averaging a 65.5% price...
CDE Grants Priority Review to Ascentage’s Olerembatinib and Roche’s Crovalimab
The Center for Drug Evaluation (CDE) has granted priority review status to two drugs: Suzhou...
Athenex Sells China Subsidiaries to TiHe Capital for USD 19 Million
US-based Athenex Inc. (Nasdaq: ATNX) announced an agreement to sell all equity interests in its...
Tasly Pharmaceuticals and Mauna Kea Form JV to Commercialize Cellvizio in China
China-based Tasly Pharmaceuticals (SHA: 600535) announced a joint venture (JV) with France’s Mauna Kea Technologies...
MicroPort MedBot’s Honghu Robot Wins FDA 510(k) Certification for Joint Replacement
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) announced that its in-house developed orthopedic surgery...
Venus Medtech’s Transcatheter Prosthetic Pulmonary Valve Approved by NMPA
The National Medical Products Administration (NMPA) has approved Venus Medtech (Hangzhou) Inc’s (HKG: 2500) transcatheter...
Hengrui Medicine’s SHR-1701 + Ameile Combo Greenlit for EGFR-Mutated NSCLC Trial
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that the National Medical Products Administration...
Eucure Biopharma Doses First Patient in YH003 + Keytruda Trial for Mucosal Melanoma
Eucure Biopharma, a subsidiary of Sino-US contract research organization Biocytogen, announced that the first patient...
Overland ADCT BioPharma Launches Global Phase III Trial for Zynlonta in DLBCL
Overland ADCT BioPharma, a joint venture between China’s Overland Pharmaceuticals and Switzerland’s ADC Therapeutics SA...
Bio-Thera Solutions Doses First Patient in BAT8006 Phase I Study for Solid Tumors
Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced that the first patient has been dosed in a...